ENDRA Life Sciences Inc.
NDRANASDAQHealthcareMedical - Diagnostics & Research
Previous close
$4.49
−$0.095 · -2.07%
NDRA company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
25
Expensive
Momentum
77
Gaining
Sentiment
52
Mixed
Risk resilience
38
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteENDRA Life Sciences Inc. specializes in advancing the capabilities of clinical diagnostic ultrasound. The company's primary development is thermo-acoustic enhanced ultrasound technology, which operates by emitting sound waves that echo off internal body components such as tissues, organs, and blood. This innovation is utilized in managing nonalcoholic fatty liver disease, meticulously monitoring temperature during thermoablative surgical procedures, detailed vascular imaging, and assessing tissue perfusion. Furthermore, ENDRA offers other diagnostic imaging modalities, including computed tomography (CT), magnetic resonance imaging (MRI), and conventional ultrasound. These instruments empower physicians to visualize internal anatomy, aiding in treatment guidance and the identification of various medical conditions like bone fractures, cancerous growths, indicators of heart disease, or internal bleeding. The company also maintains a research collaboration agreement with General Electric Company. Established in 2007, ENDRA Life Sciences Inc. is headquartered in Ann Arbor, Michigan.
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Alexander Y. Tokman
- Listed since
- Jun 30, 2017
- Employees
- 10
Market position
Day range
Current $4.49
52-week range
Current $4.49
- Open
- $4.63
- Previous close
- $4.585
- Volume
- 27.27K
- 0.99× average
- Average volume
- 27.41K
- Average daily volume
- Market cap
- 5.7M USD
- Beta
- -0.07
- Market reference 1
- 50-day average
- $4.8531
- -7.48% below average
- 200-day average
- $4.7807
- -6.08% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 3.3M USD
- P/E (TTM)
- -0.71×
- P/B (TTM)
- 0.94×
- P/S (TTM)
- 0×
- EV / EBITDA
- -0.48×
- Earnings yield
- -197.11%
- Free cash flow yield
- -145.85%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 0.00%
- Operating margin
- 0.00%
- Net margin
- 0.00%
- Return on equity
- -310.93%
- Return on assets
- -182.35%
- Return on invested capital
- -178.30%
Financial health
- Debt / equity
- 0.07×
- Current ratio
- 1.29×
- Altman Z-score
- -20
- Piotroski F-score
- 2 of 9
Financial statements
Income trends
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development | 1.85M USD | 3.19M USD | 5M USD | 6.55M USD | 5.48M USD |
| Selling, general, and administrative | 3.91M USD | 7.63M USD | 5.52M USD | 6.6M USD | 6.02M USD |
| Operating expenses | 5.76M USD | 10.82M USD | 10.52M USD | 13.16M USD | 11.5M USD |
| Interest expense | — | — | — | 21.53K USD | — |
| Depreciation and amortization | 157.29K USD | 206.17K USD | 275.45K USD | 234.26K USD | 224.42K USD |
| Operating income | −5.76M USD | −10.82M USD | −10.52M USD | −13.16M USD | −11.5M USD |
| Net income | −7.03M USD | −11.51M USD | −10.06M USD | −13.18M USD | −11.23M USD |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 55%
- 6 beats, 5 misses, 0 met estimates
- Average EPS surprise
- -22801.84%
- 11 comparable reports
- Latest EPS result
- -0.63
- Estimate -0.84 · Beat by 25.00%
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Rating distribution
4 ratingsLimited analyst sample: 4 ratings. Interpret the distribution with caution.
Recent analyst actions
NDRA news
Corporate actions
Corporate action history
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Nov 7, 2024 | 1:35 | — | — |
Stock split | Aug 20, 2024 | 1:50 | — | — |
Stock split | Dec 9, 2022 | 1:20 | — | — |
Effective Nov 7, 2024
1:35
Effective Aug 20, 2024
1:50
Effective Dec 9, 2022
1:20
NDRA peers
ETFs holding NDRA
Funds reporting this stock among their holdings, ordered by reported position size.
Continue in GoAI
Research NDRAresearch.disclaimer